Parlodel Related Published Studies
Well-designed clinical trials related to Parlodel (Bromocriptine)
[Efficacy and safety of ropinirole in the treatment of Parkinson's disease: a
multi-center, randomized, double-blind and bromocriptine-controlled trial]. [Article in Chinese] [2013]
Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. [2010.07]
Cabergoline versus bromocriptine for symptomatic treatment of premenstrual mastalgia: a randomised, open-label study. [2010.06]
A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination. [2010.05]
Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. [2010.04.06]
Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study. [2010.02]
Randomized clinical trial of quick-release bromocriptine among patients with type
2 diabetes on overall safety and cardiovascular outcomes. [2010]
Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects. [2009.03]
Clinical efficacy of novel unidirectional buccoadhesive vs. vaginoadhesive bromocriptine mesylate discs for treating pathologic hyperprolactinemia. [2008.11]
A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. [2008.06]
The effects of bromocriptine on attention deficits after traumatic brain injury: a placebo-controlled pilot study. [2008.02]
Role of bromocriptine and pyridoxine in premenstrual tension syndrome. [2007.10]
Low intensity laser therapy is comparable to bromocriptine-evening primrose oil for the treatment of cyclical mastalgia in Egyptian females. [2007.09]
Bromocriptine during pregnancy in systemic lupus erythematosus: a pilot clinical trial. [2007.09]
Superiority of newly developed vaginal suppositories over vaginal use of commercial bromocriptine tablets: a randomized controlled clinical trial. [2007.04]
Well-designed clinical trials possibly related to Parlodel (Bromocriptine)
Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome. [2011.07.12]
Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias? [2011.05]
Effect of the prolactin-release inhibitor quinagolide on lactating dairy cows. [2011.03]
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. [2010.05]
Memory encoding and dopamine in the aging brain: a psychopharmacological neuroimaging study. [2010.03]
Tolerability and safety of ropinirole versus other dopamine agonists and levodopa
in the treatment of Parkinson's disease: meta-analysis of randomized controlled
trials. [2010]
Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration. [2009.02.04]
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. [2008.08.12]
Effects of dopaminergic modulation on electrophysiological brain response to affective stimuli. [2008.01]
A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cyclosettrade mark or placebo. [2007.06.25]
Other research related to Parlodel (Bromocriptine)
Efficacy and safety of add on therapy of bromocriptine with metformin in Indian
patients with type 2 diabetes mellitus: a randomized open labeled phase IV
clinical trial. [2014]
The role of bromocriptine in the treatment of patients with active rheumatoid
arthritis. [2013]
[Qilin pills combined with bromocriptine for idiopathic hyperprolactinemic
oligoasthenozoospermia]. [Article in Chinese] [2013]
Quick-release bromocriptine for treatment of type 2 diabetes. [2011.09]
Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. [2011.09]
Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes. [2011.07]
Bromocriptine in type 2 diabetes mellitus. [2011.07]
Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome. [2011.06.30]
Neuroleptic malignant syndrome associated with bromocriptine withdrawal in Parkinson's disease--a case report. [2011.05]
Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. [2011.05]
Bromocriptine increased operant responding for high fat food but decreased chow intake in both obesity-prone and resistant rats. [2011.02.02]
Does the bromocriptine-rebound method improve embryo quality? [2011.02]
Dopaminergic challenge with bromocriptine one month after mild traumatic brain
injury: altered working memory and BOLD response. [2011]
Quick-release bromocriptine for treatment of type 2 diabetes. [2011]
Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a
systematic review of randomized controlled trials and meta-analysis. [2011]
Bromocriptine: old drug, new formulation and new indication. [2010.12]
Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. [2010.11]
Blockage of ghrelin-induced prolactin secretion in women by bromocriptine. [2010.09]
Recovery from peripartum cardiomyopathy in a Japanese woman after administration of bromocriptine as a new treatment option. [2010.08]
Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. [2010.08]
Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET. [2010.07]
Achievement of fertility in an infertile man with resistant macroprolactinoma using high-dose bromocriptine and a combination of human chorionic gonadotropin and an aromatase inhibitor. [2010.07]
Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes. [2010.02]
A comparison of bromocriptine & cabergoline on fertility outcome of
hyperprolactinemic infertile women undergoing intrauterine insemination. [2010]
Evaluation of bromocriptine in the treatment of acute severe peripartum
cardiomyopathy: a proof-of-concept pilot study. [2010]
Cabergoline versus bromocriptine for symptomatic treatment of premenstrual
mastalgia: a randomised, open-label study. [2010]
Bromocriptine--unique formulation of a dopamine agonist for the treatment of type
2 diabetes. [2010]
Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia:
eight-week randomized, single-blind, placebo-controlled, multicenter study. [2010]
Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson's disease. [2009.12.15]
Bromocriptine induces parapoptosis as the main type of cell death responsible for experimental pituitary tumor shrinkage. [2009.10.01]
Chronic lymphocytic leukemia: long-lasting remission with combination of cyclophosphamide, somatostatin, bromocriptine, retinoids, melatonin, and ACTH. [2009.06]
[Usefulness of cabergoline in patients with prolactinemia and resistant or intolerant to bromocriptine] [2009.05]
Bromocriptine reduces augmented thyrotropin secretion in obese premenopausal women. [2009.04]
Protective effect of bromocriptine against BH4-induced Cath.a cell death involving up-regulation of antioxidant enzymes. [2009.02.27]
Bromocriptine use and the risk of valvular heart disease. [2009.02.15]
Pregnancy rate following bromocriptine treatment in infertile women with galactorrhea. [2009.02]
Collaborative work on evaluation of ovarian toxicity. 15) Two- or four-week repeated-dose studies and fertility study of bromocriptine in female rats. [2009]
Protective effects of baicalin against bromocriptine induced abortion in mice. [2009]
Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesity. [2009]
[Effect of total flavones from Cuscuta chinensis on expression of Fas/FasL, PCNA and HB-EGF in SD rats model with bromocriptine-induced abortion] [2008.11]
Recovery from peripartum cardiomyopathy after treatment with bromocriptine. [2008.11]
Short-term treatment with bromocriptine improves impaired circadian growth hormone secretion in obese premenopausal women. [2008.09]
[The assessment of the mental state of patients during simultaneous treatment with psychotropic drugs, antipsychotics included, and bromocriptine] [2008.07]
Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents. [2008.07]
Solid lipid nanoparticles as delivery systems for bromocriptine. [2008.07]
Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report. [2008.01]
Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease. [2007.10.17]
Other possibly related research studies
Clomiphene and anti-oestrogens for ovulation induction in PCOS. [2009.10.07]
Smoking cessation pharmacotherapy. [2009.08]
Evidence for a noradrenergic mechanism causing hypertension and abnormal glucose metabolism in rats with relative deficiency of gamma-melanocyte-stimulating hormone. [2009.08]
Rab3B immunoexpression in human pituitary adenomas. [2009.05]
Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats. [2009.05]
Polycystic ovary syndrome and prolactinoma association. [2009]
Hair loss in women. [2009.03]
Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan. [2009.06]
[The relevance of dopamine agonists in the treatment of depression] [2009]
'Bad guys' among the antiparkinsonian drugs. [2009.03]
Antioxidant effects of some drugs on ethanol-induced ulcers. [2009.02.18]
Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine. [2009.03]
Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. [2009.01.15]
Smoking in pregnancy and lactation: a review of risks and cessation strategies. [2009.04]
Rapid left ventricular recovery after cabergoline treatment in a patient with peripartum cardiomyopathy. [2009.02]
Treatments for suppression of lactation. [2009.01.21]
[Peripartum cardiomyopathy] [2009.01.05]
High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease. [2009.02]
[Primary glucocorticoid resistance syndrome presenting as pseudo-precocious puberty and galactorrhea] [2008.09]
Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment. [2008.06]
Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretion. [2008.10]
Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. [2008.12.15]
Long-term outcome in Parkinson disease: no advantage to initiating therapy with dopamine agonists. [2008.11]
Cost effectiveness of pharmacotherapies in early Parkinson's disease. [2008]
A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs. [2008.12.12]
Somatostatin-dopamine ligands in the treatment of pituitary adenomas. [2009.06]
Immunohistochemical expression of SNAP-25 protein in adenomas of the human pituitary. [2008.10]
[Digital ischemia related to bromocriptin] [2008.10]
Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. [2008.05]
|
